ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/biliary/advanced-metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Biliary - Advanced/metastatic
14
trial(s) found.
NCT06760819
Advanced
Phase 2
Recruiting
A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (
panSOHO
)
EGFR/ERBB2 inhibitor,mutant-selective,non-covalent
Cervical cancer
Endometrial cancer
NOT Biliary tract cancer
NOT Colorectal adenocarcinoma
NOT Non-small cell lung cancer
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4215 - Southport - ICON Cancer Care
NCT06560645
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 (
PRT7732-01
)
SMARCA2 degrader
NOT Cholangiocarcinoma
NOT Ovarian small cell carcinoma
NOT Pancreatic adenocarcinoma
Non-small cell lung cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2576 - Bowral - Southern Highlands Cancer Centre
2640 - Albury - Border Medical Oncology Research Unit
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06501625
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants With Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation (
S095031-210
)
IDH1 R132 inhibitor
anti-PD-L1 monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Cholangiocarcinoma
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06467357
Advanced
Phase 3
Recruiting
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (
DESTINY-BTC01
)
anti-ERBB2 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
antimetabolite
bispecific PD-1/TIGIT antibody
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06441747
Advanced
Phase 2
Recruiting
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (
BIL-PPP
)
PARP inhibitor
anti-PD-L1 monoclonal antibody
Cholangiocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06219941
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) (
D9800C00001
)
anti-CLDN18.2 antibody-drug conjugate
Biliary tract cancer
Cancer
Gastric cancer
Pancreatic adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06109779
Curative
Phase 3
Recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) (
D7025C00001
)
bispecific PD-1/TIGIT antibody
placebo
Biliary tract cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05727176
Advanced
Phase 2
Recruiting
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements (
FOENIX-CCA4
)
pan-FGFR inhibitor,irreversible
Cholangiocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05411133
Advanced
Phase 1
Recruiting
A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies (
A001
)
bispecific T-cell engager,CDH17-targeting
Cholangiocarcinoma
Colorectal adenocarcinoma
Gastric cancer
Gastrointestinal cancer
Hepatocellular carcinoma
Oesophageal adenocarcinoma
Pancreatic cancer
NSW
2217 - Kogarah - St George Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05123482
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) (
D6900C00001
)
anti-B7H4 antibody-drug conjugate
Biliary tract cancer
Breast cancer
Endometrial cancer
Ovarian cancer
Squamous non-small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04644068
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (
PETRA
)
PARP1-selective inhibitor
Biliary tract cancer
Bladder cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT02628067
Advanced
Phase 2
Recruiting
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) (
KEYNOTE-158
)
anti-PD-1 monoclonal antibody
Anal cancer
Biliary tract cancer
Cancer
Cervical cancer
Cholangiocarcinoma
Colorectal cancer
Endometrial cancer
Endometrial carcinoma
Lung carcinoid tumour
Mesothelioma
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland cancer
Salivary gland carcinoma
Small-cell lung cancer
Solid tumour
Thyroid cancer
Vulval cancer
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (14)
Recruitment Country and State
VIC (11)
NSW (10)
WA (8)
QLD (3)
SA (2)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (4)
Phase 2 (5)
Phase 3 (2)
Trial Type
Advanced (13)
Curative (1)
Cancer Therapy Class
PD-1/PD-L1
43%
PD-1
29%
ERBB2
21%
PD-L1
21%
TIGIT
21%
PARP
21%
Trop2
14%
PARP1-selective
14%
EGFR
7%
SMARCA2
7%
IDH1
7%
IDH1 R132
7%
CLDN18.2
7%
DPD
7%
orotate phosphoribosyltransferase
7%
MET
7%
FGFR
7%
FGFR1
7%
FGFR1/2/3
7%
FGFR2
7%
FGFR3
7%
FGFR4
7%
CDH17
7%
B7H4
7%
ER
7%
oestrogen axis
7%
Facility
3168 - Clayton - Monash Medical Centre (5)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
3004 - Melbourne, Southbank - Alfred Health (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
2109 - North Ryde - Macquarie University Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
4215 - Southport - ICON Cancer Care (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2576 - Bowral - Southern Highlands Cancer Centre (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
6009 - Nedlands - Linear Clinical Research (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
3002 - East Melbourne - Epworth Freemasons (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
6009 - Nedlands - One Clinical Research (1)
2031 - Randwick - Prince of Wales Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2217 - Kogarah - St George Private Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Biliary tract cancer
Gastrointestinal cancer
Hepatobiliary cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Thoracic cancer
Pancreatic cancer
Gynaecological cancer
Cholangiocarcinoma
Endometrial cancer
Lung cancer
Respiratory tract cancer
Colorectal cancer
Lower gastrointestinal cancer
Gastroesophageal cancer
Cervical cancer
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Non-small cell lung cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Gastric cancer
Breast cancer
Ovarian cancer
Urogenital cancer
Head and neck cancer
Hepatocellular carcinoma
Oesophageal cancer
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Urothelial carcinoma
Breast adenocarcinoma
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Oesophageal squamous cell carcinoma
Triple-negative breast cancer
Colorectal adenocarcinoma
Oesophageal adenocarcinoma
Squamous non-small-cell lung cancer
Bladder cancer
Male genital cancers
Prostate cancer
Anal cancer
Endocrine gland cancer
Endometrial carcinoma
Gastro-entero-pancreatic neuroendocrine tumour
Lung carcinoid tumour
Mesothelioma
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland cancer
Salivary gland carcinoma
Thyroid cancer
Vaginal and vulvar cancer
Vulval cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy